Y-MABS THERAPEUTICS INC (YMAB) Stock Income Statement
NASDAQ:YMAB - Nasdaq - US9842411095 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 88.66M | 87.69M | 84.82M | 65.27M | 34.90M | |||
| Cost Of Goods | 15.90M | 15.00M | 11.37M | 7.47M | 2.30M | |||
| Gross Profit | 72.75M | 72.68M | 73.45M | 57.80M | 32.59M | |||
| Operating Expenses | 102.07M | 102.36M | 94.64M | 152.61M | 148.03M | |||
| Research and Development | 46.12M | 48.03M | 50.87M | 91.57M | 93.25M | |||
| Selling, General, and Administrative Expenses | 55.74M | 54.08M | 43.72M | 60.94M | 54.57M | |||
| Operating Income | -29.31M | -29.68M | -21.19M | -94.81M | -115.43M | |||
| Interest Income/Expense | N/A | 1.81M | 882.00K | 40.00K | 1.90M | |||
| Other Income/Expense | 2.30M | -426.00K | 3.92M | -800.00K | -3.75M | |||
| Non Recurring Items | N/A | -1.52M | -4.48M | N/A | N/A | |||
| Income Before Taxes | -28.53M | -29.81M | -20.87M | -95.57M | -55.28M | |||
| Income Tax | -301.00K | -146.00K | 561.00K | N/A | N/A | |||
| Net Income | -28.23M | -29.67M | -21.43M | -95.57M | -55.28M | |||
| EBITDA | -28.87M | -29.14M | -20.45M | -93.97M | -114.65M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.63 | -0.67 | -0.49 | -2.19 | -1.28 | |||
| Non GAAP EPS | -0.64 | -0.67 | -0.49 | -2.18 | -2.72 | |||
| Statistics | ||||||||
| Gross Profit Margin | 82.06% | 82.89% | 86.60% | 88.56% | 93.38% | |||
| Profit Margin | -31.84% | -33.83% | -25.26% | -146.42% | -158.40% | |||
| Operating Profit Margin | -33.06% | -33.85% | -24.98% | -145.26% | -330.74% | |||
All data in USD